

(c) having a number average of 160-10,000 nucleotide bases; and

(d) being polyadenylated.

33. The RNA of claim 32 that contains 1600-4000 nucleotide bases.--

REMARKS

Consideration of the above-identified application in view of the amendments above and the discussion that follows is respectfully requested.

I. The Amendments

The specification has been amended in numerous places to correct obvious misspellings, grammatical or typographical errors. These amendments were also made in the great grandparent application (Serial No. 516,136) or the grandparent application (Serial No. 058,620, now U.S. Patent No. 4,900,811), and the immediate parent application (Serial No. 07/476,961, now U.S. Patent 5,292,798) all of which applications are collectively referred to as the "parent". These amendments add no new matter.

New claims 26-33 have been added that are directed to complementary DNA and mRNA as are disclosed in the application. The Examiner's attention is invited to at least the disclosures of page 57, line 14 through page 61, line 3; Footnote 2 to Table III, Table III itself, and page 28, lines 24-28.

In addition, that the mRNAs and protenoids of interest here are mammalian is noted at page 17, line 31 through page 18, line 2. That a mammalian proteinoid is neuroactive is disclosed at least at original claims 4 and 13, and the specification at page 67, line 4. That an RNA of interest is located in the cytoplasm is disclosed at least in claim 10, at page 3, lines 4-9 and at page 67, lines 4-9. Claim 31 is supported at least by the descriptions of the enumerated figures.

That the messenger RNA (mRNA) is not present in cells of the liver and kidney is found in the specification at least at page 28, line 32 through page 29, line 2. That the mRNA is not present in cells of the gut, lung, heart and skeletal muscle is found at least at page 37, lines 7-9 of the specification.

It is thus seen that no new matter has been added.

II. Provisional Election

In the event that the claims of this application including those of this paper are subjected to a restriction requirement, the claims of this paper (claims 26-33) are provisionally elected without traverse.

III. Parental Prosecutions

True copies of pertinent papers filed during the parental prosecutions will be forwarded to complete this file and help speed prosecution. Those documents will be forwarded under separate cover due to their bulk.

IV. Summary

New claims 26-33 have been added and a provisional election of those claims has been made without traverse.

It is believed that the claims are in order for allowance based upon the record. An early notice of allowance is earnestly solicited.

No further fee or petition is believed to be necessary. However, should any further fee be needed, please charge our Deposit Account No. 23-0920, and deem this paper to be the required petition.

The Examiner is requested to phone the undersigned should any questions arise that can be dealt with over the phone to expedite this prosecution.

Please note that the undersigned has moved his practice to the address below, while maintaining the Power of Attorney in

this application. Please forward all further communications concerning this application to counsel at the address shown below. A separate paper noting the Change of Address and Appointment of Attorney is enclosed.

Respectfully submitted,

By 
Edward P. Gamson, Reg. No. 29,381

Enclosures

Change of Address and Associate Power of Attorney

Welsh & Katz, Ltd.
135 South La Salle Street
Chicago, Illinois 60603
312/781-9470

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this Preliminary Amendment is being facsimile transmitted to the Patent and Trademark Office to 703/305-3014 on the date shown below:

October 24, 1994.


Edward P. Gamson